Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9864420 | 0.98 | NFE2L2 (0.39) | NFE2L2CYP1A2SIGMAR1SMN1; SMN2EPHX1 | |
| SCHEMBL129003 | 0.90 | — | — | |
| SCHEMBL8986251 | 0.87 | NFE2L2 (0.42) | NFE2L2CYP1A2SIGMAR1SMN1; SMN2EPHX1 | |
| SCHEMBL8743871 | 0.85 | CYP1A2 (0.46) | NFE2L2CYP1A2SIGMAR1SMN1; SMN2EPHX1 | |
| SCHEMBL11224710 | 0.85 | CYP1A2 (0.46) | NFE2L2CYP1A2SIGMAR1SMN1; SMN2EPHX1 | |
| SCHEMBL24042735 | 0.82 | NFE2L2 (0.39) | NFE2L2CYP1A2SIGMAR1SMN1; SMN2EPHX1 | |
| SCHEMBL21938959 | 0.82 | CYP1A2 (0.44) | NFE2L2CYP1A2SIGMAR1SMN1; SMN2EPHX1 | |
| SCHEMBL28329353 | 0.82 | NFE2L2 (0.38) | NFE2L2CYP1A2SIGMAR1SMN1; SMN2EPHX1 | |
| SCHEMBL4915411 | 0.81 | NFE2L2 (0.40) | NFE2L2CYP1A2SIGMAR1SMN1; SMN2EPHX1 | |
| SCHEMBL129266 | 0.78 | HTR2A (0.31) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1655291-B1 | COMPOUNDS HAVING THROMBOPOIETIN RECEPTOR AGONISM | SHIONOGI & CO (JP) | 2016-08-03 | — | — | EP | disclosed |
| CN-102271732-A | Nanochannel devices and related methods | — | 2011-12-07 | — | — | CN | disclosed |
| US-20090318513-A1 | COMPOUNDS EXHIBITING THROMBOPOIETIN RECEPTOR AGONISM | SHIONOGI & CO., LTD. | 2009-12-24 | — | — | US | disclosed |
| US-7601746-B2 | Compounds exhibiting thrombopoietin receptor agonism | SHIONOGI & CO., LTD. (JP) | 2009-10-13 | — | — | US | disclosed |
| US-20070043087-A1 | Such as 3-{2,6-difluoro-4-[4,5-dihydro-6-(3,3-dimethylbutyl)naphtho[1,2-d]thiazol-2-ylcabamoyl)phenyl]-2-methylacrylic acid | EDDINGPHARM (HONG KONG) COMPANY LIMITED (CN) | 2007-02-22 | — | — | US | disclosed |
| EP-1655291-A1 | COMPOUNDS HAVING THROMBOPOIETIN RECEPTOR AGONISM | SHIONOGI & CO., LTD. (JP) | 2006-05-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318513-A1 | COMPOUNDS EXHIBITING THROMBOPOIETIN RECEPTOR AGONISM | MPL, TEK, GHRHR | NFE2L2 4340/4885CYP1A2 1661/4885SIGMAR1 494/4885 |
| US-20070043087-A1 | Such as 3-{2,6-difluoro-4-[4,5-dihydro-6-(3,3-dimethylbutyl)naphtho[1,2-d]thiazol-2-ylcabamoyl)phenyl]-2-methylacrylic acid | DHFR, NAT1, ACR | NFE2L2 3834/4885CYP1A2 627/4885SIGMAR1 765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.